SRRA earnings
Sierra Oncology Inc. (SRRA) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis—New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at an upcoming medical meeting— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and key secondary endpoints. "These data are extremely exciting and everything we had hoped to see from the trial," said Step
- Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline—Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (NASDAQ:AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022. "This global in-licensing deal is of two-fold importance to Sierra's long-term strategy. First, it brings